1 – 36 of 36
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
- Cytosolic Trapping of a Mitochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies (
- How is alpha-synuclein cleared from the cell? (
- 2018
- In vivo quantification of glial activation in minipigs overexpressing human α-synuclein (
- α-Synuclein Fibril Formation and the Effects of Lipid Membranes (
- Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease (
- 2017
- Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes (
- 2016
- Pathogenic effects of alpha-synuclein: modifications and toxicity (
- Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression (
- A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein (
- 2015
- A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine (
- Fluorescent Probes and Protein Misfolding: Methods and Applications (
- Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease (
- 2014
- A porous silicon immunoassay platform for fluorometric determination of alpha-synuclein in human cerebrospinal fluid (
- Alpha-Synuclein Repeat Variants and Survival in Parkinson's Disease (
- Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants (
- Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA) (
- 2013
- LAMP2A as a therapeutic target in Parkinson disease (
- Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease (
- What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? (
- Cholinergic and dopaminergic aspects of dementia in Parkinson's disease: postmortem neuropathological findings and modeling of cognitive dysfunction in rodents (
- Animal Models of Parkinson's Disease: Limits and Relevance to Neuroprotection Studies (
- Boosting chaperone-mediated autophagy in vivo mitigates alpha-synuclein-induced neurodegeneration (
- 2012
- A Pilot Study Examining Associations between DYRK1A and alpha-Synuclein Dementias (
- Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates (
- Altered CSF Orexin and α-Synuclein Levels in Dementia Patients. (
- Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. (
- 2011
- Signs of Degeneration in 12-22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson's Disease (
- Heredity in Parkinson's disease. From rare mutations to common genetic risk factors. (
- GDNF fails to exert neuroprotection in a rat {alpha}-synuclein model of Parkinson's disease. (
- A deadly spread: cellular mechanisms of α-synuclein transfer. (
- 2010
- Does A "Prion-Like" Mechanism Contribute to the Spreading of Neuropathology in Parkinson's Disease? (
- Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. (
- 2009
- Suppression of Map Kinases Inhibits Microglial Activation and Attenuates Neuronal Cell Death Induced by Alpha-Synuclein Protofibrils (
- 2008
- The effect of alpha-synuclein knockdown on MPP plus toxicity in models of human neurons (
- 2007
- High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence (
- 2002
- Ultrastructure of alpha-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells (